COPD exacerbation frequency, pharmacotherapy and resource use: An observational study in UK primary care

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 11, Issue 3, 2014, Pages 300-309

  Thomas, Mike ^a   Radwan, Amr ^b   Stonham, Carol ^c   Marshall, Sam ^d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Novartis Pharmaceuticals Uk Limited   (United Kingdom)

^c Minchinhampton Surgery   (United Kingdom)

^d PH ASSOCIATES   (United Kingdom)

Author keywords

Disease severity; Health economics; Inhaled corticosteroids; Long acting beta agonists; Long acting muscarinic antagonists; Retrospective study

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; GENERAL PRACTICE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOTHERAPY; OBSERVATIONAL STUDY; PATIENT CODING; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY HEALTH CARE; UNITED KINGDOM; CLINICAL TRIAL; DISEASE COURSE; DRUG COMBINATION; HEALTH SERVICE; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; AGED; DISEASE PROGRESSION; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; FEMALE; GREAT BRITAIN; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84900808236     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2013.841671     Document Type: Article

References (35)

1. Office for National Statistics. Mortality Statistics: Deaths registered in England and Wales 2010 (Series DR). Office for National Statistics [Internet]. Available from http://www.ons.gov.uk/ons/rel/vsob1/mortality- statistics-deaths-registeredin-england-and-wales-series-dr-/2010/index.html. Accessed 13/09/2012.
2. National Clinical Guideline Centre. (2010) Chronic Obstructive Pulmonary Disease - Management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Clinical Guideline Centre. Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/English. Accessed 16/01/2013
3. World Health Organization (WHO) 2006. Burden of COPD. World Health Organization [Internet]. Available from http://www.who.int/respiratory/copd/ burden/en/index.html. Accessed 13/09/2012
4. Department of Health 2011. An Outcomes Strategy for Chronic Obstructive Pulmonary Disease (COPD) and Asthma in England. Department of Health [Internet]. Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-127974. Accessed 13/09/2012.
5. Britton M. The burden of COPD in the U.K.: Results from the Confronting COPD survey Respir Med 2003 Mar; 97 Suppl C:S71-79. (Pubitemid 36266872)
6. Jones RC, Dickson-Spillman M, Mather MJ, Marks D, Shackell BS. Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: The Devon primary care audit. Respir Res 2008 Aug; 9(1):62.
7. British Heart Foundation statistics. Prevalence of CHD, stroke, myocardial infarction and angina, by sex and age, England2006. Available from http://www.bhf.org.uk/research/heartstatistics/morbidity/prevalence.aspx. Accessed 07/08/2013.
8. The NHS Information Centre for Health and Social Care. Disease Prevalence - Quality and Outcomes Framework (QOF) for April 2011-March 2012, England. Available from http://www.diabetes.org.uk/Professionals/Publicationsreports-and- resources/Reports-statistics-and-case-studies/Reports/Diabetes-prevalence-2012- March-2013/. Accessed 07/08/2013
9. Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ, Crapo J, Hersh CP and the COPD Gene Investigators. The clinical features of the overlap between COPD and asthma. Respir Res 2011 Sep; 12:127.
10. Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003 Dec; 22(6):931-936. (Pubitemid 37540644)
11. Jones PW, Willits LR, Burge PS and on behalf of the Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Disease severity and the effect of fl uticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003 Jan; 21(1):68-73. (Pubitemid 36150303)
12. Hurst JR, Vestbo J, Anzueto A, Locantore N, MÜllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, MacNee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA for the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010 Sep; 363:1128-1138.
13. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: A 1-year follow-up study. Chest 2003 Mar; 123(3):784-791. (Pubitemid 36315494)
14. Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.S.A.: Results from the confronting COPD survey. Respir Med 2003 Mar; 97 Suppl C:S81-89. (Pubitemid 36266873)
15. Miller JD, Foster T, Boulanger L, Chace M, Russell MW, Marton JP, Menzin J. Direct costs of COPD in the U.S.: An analysis of Medical Expenditure Panel Survey (MEPS) data. COPD 2005 Jan; 2(3):311-318. (Pubitemid 43879447)
16. Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson S, PrÜtz C. The costs of exacerbations in chronic obstructive pulmonary disease (COPD) Respir Med 2002 Sep; 96(9):700- 708.
17. Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The costs of treating COPD in the United States. Chest 2001 Feb; 119(2):344-352. (Pubitemid 32163742)
18. Gerdtham UG, Andersson LF, Ericsson A, Borg S, Jansson SA, Rönmark E, Lundbäck B. Factors affecting chronic obstructive pulmonary disease (COPD)-related costs: A multivariate analysis of a Swedish COPD cohort. Eur J Health Econ 2009 May; 10(2):217-226.
19. Jansson SA, Andersson F, Borg S, Ericsson A, Jönssen E, Lundbäck B. Costs of COPD in Sweden according to disease severity. Chest 2002 Dec; 122(6):1994-2002. (Pubitemid 36051135)
20. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez- Sala JL, Masa F, Verea H, Murio C, Ros F, Vidal R. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: A 2 year follow up study. Thorax 2004 May; 59:387-395. (Pubitemid 38624744)
21. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998 May; 157(5 Pt 1):1418-1422.
22. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centred outcomes. Chest 2007 Mar; 131(3):696-704. (Pubitemid 46446859)
23. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. The relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002 Oct; 57(10):847-852. (Pubitemid 35178607)
24. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J. Efficacy of salmeterol/fl uticasone propionate by GOLD stage of chronic obstructive pulmonary disease: Analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009 Jun; 10:59.
25. Calverley P, Pauwels RA, Jones PW, Anderson JA, Vestbos J. The severity of airways obstruction as a determinant of treatment response in COPD. Int J Chron Obstruct Pulmon Dis 2006 May; 1(3):209-218.
26. Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009 Sep; 34(3):641-647.
27. Singh S, Loke YK. Risk of pneumonia associated with longterm use of inhaled corticosteroids in COPD: A critical review and update. Curr Opin Pulm Med 2010 Mar; 16(2):118-122.
28. Decramer M, Bartsch P, Pauwels R, Yernault JC. Management of COPD according to guidelines. A national survey among Belgian physicians. Monaldi Arch Chest Dis 2003 Jan-Mar; 59(1):62-80. (Pubitemid 37203282)
29. Asche CV, Brixner DI, Conoscenti CS, Young DC, Shah H, Amy P. Assessment of physician prescribing for primary care patients with chronic obstructive pulmonary disease (COPD) in a national electronic medical record (EMR) research database [Abstract]. Chest 2006 Oct; 130(4):175S-b-175S.
30. Van Andel AE, Reisner C, Menjoge SS, Witek TJ. Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987-1995. Chest 1999 Mar; 115(3):703-707. (Pubitemid 29129948)
31. Peperell K, Rudolf M, Pearson M, Diggle J. General practitioner prescribing habits in asthma/COPD. Asthma Gen Practice 1997 Dec; 5(2):29-30. (Pubitemid 28256836)
32. De Miguel-Diez J, Carrasco-Garrido P, Rejas-Gutierrez J, Martin-Centeno A, Gobartt-Vázquez E, Hernandez-Barrera V, Gil de Miguel A, Jimenez-Garcia R. Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status. Lung 2011 Jun; 189(3):199-206.
33. Roche N, Lepage T, Bourcereau J, Terrioux P. Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease. Eur Respir J 2001 Dec; 18(6):903-908. (Pubitemid 34092861)
34. Nadeem NJ, Taylor SJ, Eldridge SM. Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology. Respir Res 2011 Aug; 12:107.
35. Rutschmann OT, Janssens JP, Vermeulen B, Sarasin FP. Knowledge of guidelines for the management of COPD: A survey of primary care physicians. Respir Med 2004 Oct; 98(10):932-937. (Pubitemid 40029123)